What Is Euphorinol (EPN)? The Real Molecule, the Fake Name, and How It Is Made

Euphorinol, sold under the trade code EPN, is THC butanenitrile oxime: a fully synthetic cannabinoid with the formula C₂₂H₂₈N₂O₃ and an exact mass of 368.21, first reported by the Makriyannis laboratory in 2018 as a deliberately short-acting CB1 agonist (PubChem CID 145984840). It was never in a cannabis plant and it is not a blend of CBD and CBG. The “unknown cannabinoid at 368” that third-party laboratories keep finding on super sativa products is this molecule. It is built in seven chemical steps from 3′,5′-dimethoxyacetophenone, an industrial ketone, and the final step installs an oxime ether, a carbon-nitrogen double bond that no enzyme in cannabis can make. The name printed on supplier documents, tetrahydromethylisopentyl-ethylcannabinol, is not a chemical name and describes no molecule.

The short answers to the questions people actually type: it is intoxicating, it is a THC analog in the structural sense, it loses hemp status under federal law on November 12, 2026, it has no human safety data, and whether it trips a drug test is unknown because nobody has published its metabolism. The chemistry behind each of those answers is below, followed by the seven-step route that produces it.

Everything written about this molecule in the retail market is either marketing copy or a guess. This article is the chemistry.

Euphorinol (EPN) at a Glance

Why “Tetrahydromethylisopentyl-ethylcannabinol” Is Not a Chemical Name

Every reseller page carries the same name for the active ingredient, copied from one supplier’s technical sheet: tetrahydromethylisopentyl-ethylcannabinol. Four tests settle whether a string like that describes a molecule, and this one fails all four.

It has no locants. A chemical name tells you where each group sits by number. “Methyl,” “isopentyl,” and “ethyl” with no positions means three substituents floating somewhere on a ring system. Hand that name to two chemists and they will draw two different compounds, which means the name does not specify one.

It is built on the wrong parent. Cannabinol is a specific molecule, CBN, the fully aromatic oxidation product of THC. “Tetrahydrocannabinol” is already the name of THC. Bolting alkyl groups onto that name describes a THC carrying extra hydrocarbon stubs. THC already has a pentyl chain at the 3 position, so “isopentyl” either duplicates it or renames it, and neither reading tells a chemist anything about the oxime that defines the compound.

The mass does not work. THC is C₂₁H₃₀O₂ at 314. Add a methyl and an ethyl and you reach 356. Add the isopentyl as a fourth group and you reach 426. Swap it for the existing pentyl and you are back at 356. No reading of the name lands at 368, the mass on every certificate. The name also contains no nitrogen, and the compound in the vial contains two, one in the oxime and one in the nitrile. A name with no nitrogen cannot describe a molecule whose defining functional group is a carbon-nitrogen double bond.

No registry has it. There is no CAS number, no PubChem record, and no entry in any forensic or new-psychoactive-substance database under that name. A supplier that had characterized its molecule would print a CAS number on the safety data sheet. Ask for the SDS. If the identity line carries that string and no CAS number, the supplier has told you in writing that they do not know, or will not say, what they are selling.

The real name has been public since 2018. The compound sits in PubChem with its structure, formula, and exact mass, and the paper that first made it describes the whole oxime series. A supplier choosing an invented name over a published one is making a choice, and buyers should read it as one.

What Is Actually in an EPN Vape, Gummy, or “EPN Flower”

No product on the market is Euphorinol. Products contain it, at low single-digit percentages, inside a carrier that does the compliance work on paper. Read a bulk EPN certificate from the top and the same pattern appears every time.

The formats follow from that table. Disposable vapes and cartridges carry the blend as a distillate. Gummies and tinctures carry it in oil. “EPN flower” is hemp flower with the blend sprayed on. Bulk material is sold as a low-percentage blend in CBD and CBG distillate, and the percentage of the active is the one number most product pages never print.

Is Euphorinol Legal?

The hemp argument for Euphorinol rests entirely on the carrier. The 2018 Farm Bill defined hemp as the plant and its derivatives, extracts, cannabinoids, and isomers at no more than 0.3% delta-9 THC. A molecule assembled from an industrial ketone is none of those. It was never derived from the plant because it was never in the plant, and dissolving it in CBD distillate does not change where it came from.

Federal law now says this explicitly. Section 781 of Public Law 119-37, signed November 12, 2025, removes from the hemp definition every cannabinoid the plant cannot naturally produce, effective November 12, 2026. H.R. 6500 pushed the plant-derived restrictions to December 11, 2026 and left the synthetic date alone. Euphorinol falls on the earlier date, alongside HHC, THC-O acetate, and every other synthesized analog. Our breakdown of the 2026 intoxicating hemp ban covers the two clocks and the 0.4 mg per container cap that applies to everything else.

Before that date, the exposure is the one every synthetic THC analog already carries. THC butanenitrile oxime is a tetrahydrocannabinol with a modified side chain, sold for human consumption, which is the fact pattern the Federal Analogue Act was written for. DEA’s 2023 letter on THC-O acetate, that a cannabinoid obtained only by synthesis is not hemp, applies to this molecule word for word. Outside the United States, Hungary and Turkey have scheduled both the delta-8 and delta-9 isomers by name, and the compound circulated in Germany and Russia before it reached American shelves. State law adds a third layer: most states that ban “synthetic cannabinoids” define the term broadly enough to cover a designed molecule regardless of the carrier, and our state-by-state licensing guide tracks which ones have moved.

Is Euphorinol Safe?

The 2018 paper that first made this molecule was looking for a THC analog that wears off quickly. The series was designed so the oxime link is metabolized fast, and the lead compound showed onset around 20 minutes and duration around 180 minutes in rodents, against more than 24 hours for the long-acting comparator in the same study. That design goal is the entire safety record. There is no human pharmacokinetic study, no toxicology package, no repeat-dose data, and no published metabolite identification for either the nitrile or the oxime.

Two findings in that paper matter more to a consumer than the duration. One oxime geometry is a CB1 agonist with sub-nanomolar affinity, and the other is a neutral antagonist at the same receptor. Both geometries come out of the condensation in Step 6, and the ratio depends on how the step was run. Material that skipped the chromatography in Step 7 ships an agonist and its own antagonist in one vial at a ratio nobody measured. European market samples have also been reported as racemic, with half the mass as the inactive enantiomer, so dose-to-effect drifts between lots sold under the same name.

Then the route itself. Step 5 uses a silver salt, and silver that survives purification ends up in a cartridge; the only test that catches it, ICP-MS for silver, is almost never on the certificate. Step 6 runs in pyridine, and a product that was never chromatographed carries whatever pyridine the workup missed. The precise answer to “is Euphorinol safe” is that the molecule was designed to be short-acting, the batches on the market were not made to the standard of the paper that designed it, and nobody has measured what either fact does in a human.

Does Euphorinol Show Up on a Drug Test?

Nobody knows, and the reason is structural. Workplace urine screens are immunoassays raised against THC-COOH, the carboxylic acid metabolite of delta-9 THC. THC butanenitrile oxime is not THC, and no published study has identified what a human liver turns it into, so there is no basis for saying its metabolites do or do not cross-react with that antibody. The confirmatory method, GC-MS or LC-MS/MS, reports only what it was asked to look for, and no standard workplace panel includes this compound.

The practical risk is the carrier. EPN products are CBD and CBG distillate blends, and distillate carries THC unless someone removed it. Material sold as THC-free has tested otherwise, and regular use of a full-spectrum cartridge can produce a positive on its own. Anyone facing a test should treat an EPN cartridge like a full-spectrum CBD cartridge of unknown provenance, and should not lean on a certificate whose THC line reads non-detect from a panel with no printed limit of quantitation. Our guide to detecting converted THC covers what a laboratory can and cannot see in material like this.

What Euphorinol Actually Is

Start by throwing out the product page language. Euphorinol is described across the hemp market as a “newly discovered hemp compound,” a “proprietary terpene-rich multi-cannabinoid blend,” and a product of “advanced molecular refinement of super sativa strains.” Those three descriptions are mutually exclusive, and none of them describes a synthesis.

Euphorinol is a semi-synthetic cannabinoid in the structural sense that matters: it carries the tricyclic benzochromene framework that defines the cannabinoid class, built by the same ring-closure logic that produces THC from a resorcinol and a terpene, and then it carries a functional group that cannabis biosynthesis has no pathway to. The core is cannabinoid. The decoration is not.

That distinction controls everything downstream. A cannabinoid skeleton means it fits the general shape that the CB1 binding pocket recognizes. An oxime ether on a cannabinoid skeleton means no plant material, no reference standard, no toxicology package, and no chromatographic method that was ever validated against it. Analytical chemistry can only find what it has been taught to look for, and nobody taught the instruments this one.

For comparison, the semi-synthetics the industry already knows are modifications of a cannabinoid that already existed. HHC is THC with the double bond hydrogenated away. Delta-8 is delta-9 with the olefin slid one position downhill. THCP is the same scaffold with a longer side chain. We cover those routes in detail in our guide to novel cannabinoid synthesis from CBD. Every one of them starts with a cannabinoid and edits it. Euphorinol starts with a benzene ring that is not a cannabinoid, assembles the cannabinoid, and then edits that. It is a longer road and a completely different kind of work.

The Starting Material Nobody Expects

3′,5′-dimethoxyacetophenone is a small, cheap, commercially available molecule. An aromatic ring sits in the middle. Two methyl ether groups hang off it, one at each end. A ketone hangs off the side, a carbon double bonded to oxygen with a methyl cap.

It gets chosen for one reason: the substitution pattern is already right. Those two oxygens sit exactly where a cannabinoid A-ring needs its oxygens. Buy the pattern instead of building it, and you skip an entire synthetic campaign.

The problem is that both features are in the wrong state at the same time. The oxygens are locked behind methyl caps, so they cannot participate in a ring closure. The ketone is wide open, so it will be attacked by the Lewis acid catalyst that performs the ring closure. You cannot fix both at once, and the order you fix them in is the entire design of the route. Fix the ketone first and the demethylation that follows leaves it untouched. Fix the ring first and the ketone sits exposed through four more steps waiting to be destroyed.

The Seven Steps and Why Each One Exists

Here is the route, the purpose of each operation, and what happens to the batch when an operator decides a step looks optional.

Step 1: Protect the Ketone Before It Becomes a Liability

1,2-ethanedithiol is a two-carbon chain with a sulfur atom on each end. Under boron trifluoride catalysis, those two sulfurs displace the ketone oxygen and close around the carbonyl carbon to form a five-membered ring, a 1,3-dithiolane.

The question any chemist should ask is why sulfur and not oxygen. An ordinary acetal protecting group uses a diol and gives a dioxolane, which is easier to install and easier to remove. It is also useless here. Dioxolanes are cleaved by Lewis acids, and this route runs a Lewis acid through the molecule at the ring closure. The protecting group would come off exactly when it is needed most.

Sulfur solves it through hard and soft acid-base behavior. Boron reagents are hard acids and they bind preferentially to hard donors, which means oxygen. Sulfur is soft and large and polarizable, and the boron catalyst walks straight past it. The dithiolane sits on the molecule for four more steps, chemically invisible to the one reagent that would otherwise destroy the carbonyl it protects. That is the whole reason the first step of a cannabinoid synthesis involves a thiol that smells like a gas leak at concentrations below one part per billion.

Step 2: Boron Tribromide Takes the Caps Off

Those two methyl ethers are blocking the positions the molecule needs. Boron tribromide removes them.

The mechanism is worth stating precisely, because the usual shorthand gets it wrong. BBr3 coordinates to the ether oxygen through its empty p orbital, which turns that oxygen into a leaving group assembly. A bromide ion then attacks the methyl carbon and displaces it as methyl bromide gas. What remains on the ring is not yet a phenol. It is an aryl dibromoborinate ester, and the free phenol only appears when the reaction is quenched and that boron ester is hydrolyzed. Both methyl ethers are cleaved in the same pot by excess reagent, not one after the other. When both are gone and the quench is complete, the dimethoxyphenyl has become a resorcinol, two free hydroxyls on the ring, and that resorcinol is the future A-ring of the cannabinoid.

This is the most hazardous step in the procedure, and the reason has nothing to do with the cannabinoid. BBr3 reacts violently with water. Not liquid water in a beaker. Moisture. Humidity on glass. A joint that was not dried properly. Every piece of glassware is oven dried and cooled under nitrogen in a desiccator before the reagent is unsealed, and the reactor is purged with dry nitrogen before anything goes into it.

The off-gas problem is the part operators underestimate. The reaction generates hydrogen bromide, and the quench generates far more of it in a short window. A mineral oil bubbler cannot absorb that gas load and will blow out. A caustic gas scrubber with a backflow trap between it and the reactor is the only acceptable configuration, and the scrubber stays connected through the end of the quench, not just during the addition.

Then there is the methyl bromide. OSHA sets a ceiling limit of 20 ppm with a skin notation, and NIOSH does not publish a recommended exposure limit at all, because it classifies methyl bromide as a potential occupational carcinogen and advises reducing exposure to the lowest feasible concentration. The part that gets missed is simpler than either number: standard acid gas respirator cartridges do not capture alkyl halides. An operator wearing a full-face respirator with acid gas and organic vapor cartridges is protected against the hydrogen bromide and is not protected against the methyl bromide. The fume hood is the primary engineering control for that exposure, and no cartridge substitutes for it. If you take one piece of hazard information away from this article, make it that one.

Step 3: Attach the Terpene

With the resorcinol exposed and the ketone still hidden, the terpene goes on. The partner is a monoterpenoid alcohol carrying an isopropenyl group, and it supplies the carbon skeleton that becomes the C-ring.

Under p-toluenesulfonic acid catalysis in dichloromethane, the terpene’s tertiary alcohol ionizes and leaves as water, generating a tertiary carbocation. Resorcinol rings are strongly electron rich, because two hydroxyl groups donate into the ring and light up the positions between and beside them. That electron-rich ring attacks the carbocation in a Friedel-Crafts type alkylation and forms one new carbon-carbon bond.

The product at this point is still an open chain. It has the aromatic ring, it has the terpene, and it is not a cannabinoid. Anyone who has run a CBD isomerization recognizes the position immediately, because CBD is also an open-chain resorcinol-terpene adduct waiting for a ring closure. The chemistry that converts CBD to THC is the same ring closure, which is why the choice of acid catalyst drives selectivity in both cases.

Step 4: Close the Ring and Control Where the Double Bond Lands

Boron trifluoride etherate promotes the intramolecular cyclization. A resorcinol oxygen swings in, attacks an electrophilic carbon on the terpene fragment, and closes the pyran ring. The molecule folds into the tricyclic benzochromene framework, and that framework is the cannabinoid skeleton.

Temperature governs the outcome and nothing else does. Keep the reactor cold while the Lewis acid goes in, then warm it gently. Let the exotherm run and the olefin migrates from the delta-9 position to the delta-8 position, which is the thermodynamically favored location. This is the same energy landscape that decides whether a conversion reactor produces delta-9 or drifts to delta-8, covered in our CBD to THC isomerization guide. The molecule always wants to slide downhill. Control the heat and you control where it stops.

This is the step where the dithiolane earns its place in the route. The Lewis acid that closes this ring would have coordinated a free ketone and taken the batch apart. It walks past the thioacetal without noticing it.

Step 5: Silver Pulls the Protecting Group Off

The dithiolane has done its job and now it is in the way, because the final step needs the ketone back.

Silver nitrate in aqueous ethanol handles the removal. Silver is thiophilic, meaning it has a strong affinity for sulfur, and silver ions coordinate to both sulfur atoms of the thioacetal and weaken the carbon-sulfur bonds until the ring falls apart and the carbonyl returns. A dark precipitate forms and drops out of solution as the reaction proceeds, which is silver binding sulfur and dragging it out of the equilibrium. Filtering that solid through a Celite pad leaves the methyl ketone clean in the filtrate.

Two operational notes that matter more than they look. The filter cake is heavy metal waste of uncharacterized composition. It is commonly assumed to be silver sulfide, and assuming is not the same as knowing, so it goes to a labeled heavy metal waste stream wet, immediately, and it does not dry on the filter. And silver-contaminated glassware gets rinsed with water first, never acetone. Residual silver also becomes a release specification problem later, which is why ICP-MS for silver belongs on the final product test panel and not on a wish list.

Step 6: The Step That Makes It Euphorinol

Everything up to this point produced a tricyclic methyl ketone, a competent cannabinoid-type molecule that is not yet the target. The sixth step is the one that separates this compound from every cannabinoid in the plant.

An O-alkylhydroxylamine reagent condenses with that ketone in pyridine with acetic acid. The nitrogen of the hydroxylamine attacks the carbonyl carbon, water leaves, and what forms is an oxime ether: a carbon-nitrogen double bond with an oxygen-linked side chain, sitting where a simple carbonyl used to be. Pyridine acts as the base and the solvent, acetic acid catalyzes the dehydration, and the equilibrium is driven by removing water.

Cannabis has no biosynthetic route to a carbon-nitrogen double bond on a cannabinoid skeleton. There is no enzyme for it, no precursor pool for it, and no reason for a plant to build one. The marketing language about a compound “discovered in super sativa strains” dies on this step. This is a designed molecule and the design is deliberate.

The condensation also produces two geometric isomers, because a carbon-nitrogen double bond has two faces the way a carbon-carbon double bond does. In the E isomer the substituents sit on opposite sides of that double bond, and in the Z isomer they sit on the same side. Thermodynamics strongly favors E for O-alkyloximes of methyl aryl ketones, so E dominates the crude mixture and Z shows up as the minor component. Both are real compounds. Both end up in the product if nobody separates them.

Step 7: Separate the Isomers or Admit You Did Not

Flash chromatography on silica gel with a hexane and ethyl acetate gradient resolves the two isomers and strips the byproducts. Fractions get checked analytically before pooling, and the purified major isomer is Euphorinol.

The step is not optional and it is the one most likely to be skipped at commercial scale, because chromatography is slow, consumes solvent, and costs recovery. Skipping it means shipping a two-component mixture under a single-compound name, with whatever pyridine survived the workup riding along. If you want to understand why that residual pyridine matters at release, our guide on purging residual solvents covers the class limits that apply.

Why This Is the Most Dangerous Route in Cannabinoid Chemistry

Isomerization labs handle acids and flammable solvents. This route handles a violently water-reactive reagent, a thiol that is acutely toxic by every route of exposure, a heavy metal oxidizer, and two halogenated solvents, and it generates two toxic gases as byproducts of normal operation.

Read that table as a staffing document, not a shopping list. A facility that runs hydrocarbon extraction has engineering controls built for flammability. This route needs controls built for acute toxicity and gas handling, which is a different competency, a different hood specification, and a different waste contract. The two skill sets overlap less than people assume.

If you want the fundamentals behind this kind of work taught properly, with the lab walkthroughs and the documentation practice that makes it transferable to your own bench, that is what we built extractiontraining.com for.

Why Your Lab Report Says Unknown Cannabinoid

Here is where the chemistry collides with the market. Independent analysts tracking “super sativa” products through 2025 and 2026 kept finding the same thing on third-party certificates: a peak the instrument could see clearly and could not name, reported as an unknown cannabinoid at mass 368. For scale, THC sits at 314 and HHC at 316. A 368 entity is a substantially heavier and more decorated molecule than anything the plant produces.

That mass has a name. THC butanenitrile oxime, C₂₂H₂₈N₂O₃, has a monoisotopic mass of 368.21, and it is the only cannabinoid-type structure on record that carries a nitrogen-bearing functional group and lands on that number. It has sat in PubChem since the 2018 paper that first made it. The reason a certificate still prints “unknown” is that no cannabis testing laboratory carries it in a calibration set, so the instrument reports a mass and a retention time and the method has nothing to match them against.

The same analytical signature has surfaced under at least four different commercial labels, and in several cases under none at all. One certificate carried the disclaimer “naming and standard provided by the customer,” which is a laboratory telling you in writing that the compound name on the report came from the person selling the product. In other reports on the same product lines, the peak is absent from the results table entirely, leaving a certificate that shows only CBD and CBG and presents a clean compliance picture for material whose effects come from something that was left off the page.

Put those rows together and the “no detectable THC” claim on an EPN certificate becomes readable. It may be perfectly true and still tell you nothing, because the panel that produced it was calibrated for plant cannabinoids and the active ingredient was never in the calibration set. A non-detect for a compound the method cannot see is not a finding. This is the same structural problem we documented in our work on cannabis lab testing fraud, except here it does not require anyone to cheat. The method simply was not built for the molecule.

The analytical gap is not unique to this compound either. A 2025 paper in Drug Testing and Analysis identified three previously unknown tetrahydrocannabinol analogs circulating in the European market under trade names, and the authors noted the same structural problem: the compounds have no spectroscopic or chromatographic reference data, have never been found in cannabis plants, and cannot be identified by standard forensic chromatographic methods without spectroscopic work. Naming a molecule in a catalog does not create a method for it.

One more point, stated plainly because the market will not state it. Material sold under the EPN name is not consistent. Buyers have reported receiving product that failed on the exact specification it was sold against. A trade name is not a specification, and a certificate without a named standard behind it is a document, not evidence.

Common Failures and How to Diagnose Them

Seven ways this route goes wrong, in the order you will meet them.

Symptom: The demethylation turns into a dark tar instead of a clean product.
Root cause: Moisture. Boron tribromide hydrolyzes on contact with trace water, which consumes reagent and generates acid in the pot that attacks the substrate.
Diagnostic test: Karl Fischer titration on the solvent lot and a review of the glassware drying record. Tar that appears immediately on addition points at the glassware, tar that develops over the aging period points at the solvent.
Fix: Fresh oven-dried glassware cooled under nitrogen, verified dry solvent, and restart. There is no recovering the batch.

Symptom: The cyclization produces the wrong double bond position, delta-8 where delta-9 was intended.
Root cause: The exotherm got away during Lewis acid addition. The delta-8 position is thermodynamically downhill and heat is the permission slip.
Diagnostic test: The olefinic region of the proton NMR separates the two, and chromatographic retention against a qualified reference confirms it.
Fix: Control the addition rate so the jacket stays ahead of the reaction, and keep the warming gentle afterward. Do not try to isomerize it back.

Symptom: Residual thioacetal survives the silver step, and the next step stalls.
Root cause: Insufficient silver charge relative to the actual mass carried forward, or not enough contact time for the precipitate to drive the equilibrium.
Diagnostic test: Thin layer chromatography shows the protected spot persisting alongside the ketone product spot.
Fix: Additional silver charge and extended contact. Calculate the charge from the measured mass entering the step, never from the original starting material.

Symptom: The oxime condensation stalls with ketone still present long after it should have converted.
Root cause: Degraded hydroxylamine reagent. These reagents are not shelf-stable indefinitely and the hydrochloride salt can carry water.
Diagnostic test: Run NMR on the reagent itself before blaming the reaction. Most teams spend a day troubleshooting the pot when the bottle was the problem.
Fix: Verify reagent identity and purity on receipt and before each campaign, and replace it rather than pushing the reaction harder.

Symptom: Pyridine shows up in the chromatography fractions and in the final residual solvent panel.
Root cause: Inadequate acid washing during the workup. Pyridine is basic and it does not leave on the rotary evaporator alone at the scale this reaction uses it.
Diagnostic test: Residual solvent GC against the ICH Q3C class limits, plus the smell, which arrives before the data does.
Fix: Additional acid washing of the crude, then re-dry and re-chromatograph. Strip the bulk of the base before the acid wash rather than relying on the wash alone.

Symptom: The gas scrubber solution changes color or its pH falls during the demethylation.
Root cause: The caustic charge is exhausted and the scrubber is passing acid gas instead of capturing it.
Diagnostic test: Monitor the scrubber liquid continuously during addition and quench, not just at setup.
Fix: Replace the charge before continuing. If the frit stops bubbling entirely, stop the addition or quench immediately and vent through a secondary purged line. Never clear a blocked frit while the reactor is live.

Symptom: Residual silver exceeds specification at release, after everything else passed.
Root cause: Silver carried through the filtration and survived the workup and the column.
Diagnostic test: ICP-MS. Nothing else on a normal release panel will see it.
Fix: Additional aqueous washing of the organic phase and re-chromatography, then re-test. Build the test into the release panel permanently rather than running it once to prove a point.

What a Buyer Should Demand Before Writing a Check

If you are sourcing this material rather than making it, the questions below separate a real supply chain from a sales deck. None of them are unreasonable and all of them are answerable by anyone who actually made the compound.

• A named compound with a structure, not a trade code. EPN, HPC, and STV are commercial labels. Ask for the structure and the systematic name. A supplier who cannot draw the molecule did not make it.
• Identity by spectroscopy, not retention time. Proton NMR for connectivity and oxime geometry, high-resolution MS for formula. Retention time alone identifies nothing when no standard exists.
• A stated isomer ratio with the method behind it. The condensation makes two geometric isomers. A certificate that never mentions a minor isomer was not looking for one.
• Residual silver by ICP-MS. This route puts a heavy metal in the pot. If the panel has no metal on it, the panel was written for plant extract.
• Residual solvents against the ICH Q3C classes, including pyridine and the halogenated solvents. A standard cannabis panel does not include them, so a clean standard panel is not an answer.
• Batch records that show the mass carried into each step. This route calculates reagent charges from measured intermediate mass, not from the starting material. A supplier with no intermediate masses ran it blind.

Any supplier who answers all six is running a real process. Most of what circulates under this name will not clear the first bullet.

Frequently Asked Questions

What is Euphorinol?

Euphorinol is the trade name for THC butanenitrile oxime, a fully synthetic cannabinoid with the formula C₂₂H₂₈N₂O₃ and an exact mass of 368.21, first made by the Makriyannis laboratory in 2018 as a short-acting CB1 agonist. It is sold under the code EPN, usually as a few percent of a CBD and CBG distillate blend in vapes, gummies, tinctures, and sprayed flower. It was never in a cannabis plant. It is built in seven steps from an industrial ketone, and the final step installs an oxime ether that no plant enzyme can make.

Is Euphorinol legal?

Under federal law it stops being hemp on November 12, 2026, because Section 781 of Public Law 119-37 removes every cannabinoid the plant cannot naturally produce from the hemp definition on that date. Until then it carries the same exposure as HHC and THC-O acetate: a synthesized THC analog sold for human consumption, which DEA has said is not hemp. Hungary and Turkey have scheduled it by name, and many state synthetic-cannabinoid bans already cover it.

Does Euphorinol show up on a drug test?

Unknown. Urine screens target THC-COOH, the metabolite of delta-9 THC, and nobody has published what a human liver turns THC butanenitrile oxime into, so cross-reactivity cannot be ruled in or out. The practical risk is the carrier: EPN products are distillate blends, material sold as THC-free has tested otherwise, and regular use of a full-spectrum cartridge can produce a positive by itself.

Is Euphorinol the same as THC-O?

No. THC-O acetate is an ester made by acetylating THC’s phenol. THC butanenitrile oxime, sometimes abbreviated THCO, is an oxime ether built on the side chain, with two nitrogens in the molecule and a mass of 368 against 356 for THC-O acetate. They share an abbreviation and nothing else.

Is tetrahydromethylisopentyl-ethylcannabinol a real compound?

No. The name has no position numbers, so it does not specify a structure. It contains no nitrogen, and the compound sold as EPN contains two. No reading of the name produces a molecule at mass 368, and it has no CAS number, no PubChem record, and no entry in any forensic database. It appears on one supplier’s technical sheet and was copied from there onto every reseller page.

What is in an EPN vape?

A CBD and CBG distillate carrier, published bulk certificates show around 40% CBD and 28% CBG, with THC butanenitrile oxime at low single-digit percent, botanical terpenes, and in some lots detectable THC. The active is the one line most certificates either leave blank, report as an unknown peak at 368, or name using a standard the seller supplied.

How is Euphorinol made?

Euphorinol is made by total construction of a cannabinoid skeleton followed by a functional group modification, in seven steps from 3′,5′-dimethoxyacetophenone. The ketone is protected as a dithiolane, both aryl methyl ethers are removed with boron tribromide to expose a resorcinol, a monoterpenoid alcohol is coupled under acid catalysis, boron trifluoride closes the pyran ring to form the tricyclic cannabinoid framework, silver nitrate removes the protecting group to regenerate the ketone, a hydroxylamine reagent converts that ketone to an oxime ether, and chromatography separates the major geometric isomer. It is a synthesis, not an extraction.

What is EPN cannabinoid?

EPN is the trade code attached to material sold as Euphorinol, and the chemistry behind the code is THC butanenitrile oxime: an oxime ether on a cannabinoid skeleton, a carbon-nitrogen double bond carrying an oxygen-linked side chain where a carbonyl would normally sit. That bond does not occur in cannabis. The complication is that EPN functions as a commercial label rather than a specification, and the same analytical signature has appeared on certificates under several different names and, in some reports, under no name at all.

Is Euphorinol natural or synthetic?

Synthetic in the part that matters. The starting material is an industrial ketone with no cannabis origin, and the cannabinoid skeleton is assembled in the reactor rather than harvested. Suppliers describe it as semi-synthetic or as a product of molecular refinement of specific cannabis strains. Refinement implies you started with the compound and purified it, and nothing in this route starts with a cannabinoid.

Why does Euphorinol show up as an unknown cannabinoid on a COA?

Because no certified reference standard exists for it. A cannabinoid potency panel quantifies the compounds in its calibration set and reports everything else as either absent or as an unidentified peak, depending on how the laboratory writes its reports. Analysts tracking these products have repeatedly reported the same unidentified entity at mass 368, against 314 for THC and 316 for HHC. The instrument can see it. The method cannot name it.

Does Euphorinol contain THC?

The compound described by this route is not THC and does not contain THC as a structural component. Whether a given product contains THC is a separate question that depends on the manufacturer, and buyers have reported material sold as THC-free that tested otherwise. A non-detect result from a panel that was never validated for the active ingredient is a weak basis for any compliance claim.

Why is a dithiolane used instead of an ordinary acetal?

Because the route runs a Lewis acid at the ring closure, and ordinary oxygen acetals are cleaved by Lewis acids. The protecting group would come off exactly when it is needed. Sulfur is a soft donor and boron reagents are hard acids, so a thioacetal is effectively invisible to the catalyst and survives to the deprotection step.

Is Euphorinol safe?

There is no published toxicology package, no human pharmacokinetic data, and no peer-reviewed safety literature on this compound in people. The 2018 paper that designed it was aiming for a short-acting CB1 agonist and reported rodent onset around 20 minutes and duration around 180 minutes; that is the whole record. Market batches add unmeasured ratios of the agonist and antagonist oxime geometries, racemic material in some European samples, and whatever silver and pyridine survived a route that was never chromatographed. Absence of evidence is not evidence of safety, and the honest answer is that nobody knows.

How is this different from making HHC or delta-8?

Both of those start with a cannabinoid and edit it, usually in one or two steps, with reagents most conversion labs already own. This route builds the cannabinoid first, over four steps, before it modifies anything, and the reagent list includes a water-reactive boron halide, a toxic thiol, and a silver salt. The engineering controls, the waste streams, and the analytical burden are all in a different category.

Ready to level up your extraction game? Contact WKU Consulting for personalized guidance on building your extraction lab.

For more deep dives into cannabis chemistry, extraction SOPs, and lab design, subscribe to the WKU Consulting YouTube channel.

Watch a related video: